USE OF ANTIBIOTICS AS VACCINE ADJUVANTS

USE OF ANTIBIOTICS AS VACCINE ADJUVANTS

FIELD: medicine, chemical-pharmaceutical industry, microbiology, pharmacy. ^ SUBSTANCE: invention relates to an adjuvant composition comprising antibacterial agent azalid tulathromycin wherein azalid acts as adjuvant. Also, invention relates to vaccine comprising some components and involving: (A) a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LEJ REHNDI DIN, O`KHARA MAJKL KENNET, MAKGEHJVIN DEHVID ROSS
Format: Patent
Sprache:eng ; rus
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator LEJ REHNDI DIN
O`KHARA MAJKL KENNET
MAKGEHJVIN DEHVID ROSS
description FIELD: medicine, chemical-pharmaceutical industry, microbiology, pharmacy. ^ SUBSTANCE: invention relates to an adjuvant composition comprising antibacterial agent azalid tulathromycin wherein azalid acts as adjuvant. Also, invention relates to vaccine comprising some components and involving: (A) at least one antigen wherein antigen is chosen from group consisting of M. haemolytica antigen, M. haemolytica leukotoxin, M. haemolytica capsule antigen, M. haemolytica soluble antigen, or their mixture, and (b) at least one azalid, for example, tulathromycin wherein azalid acts as adjuvant. Adjuvant or vaccine compositions are used for prophylaxis and treatment of diseases caused by pathogenic factor, cancer cell or allergen in animal but not in human. Proposed adjuvant provides enhancing effectiveness of the vaccine composition. ^ EFFECT: improved and valuable medicinal properties of composition. ^ 10 cl, 16 tbl, 2 dwg, 5 ex
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_RU2322241C2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>RU2322241C2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_RU2322241C23</originalsourceid><addsrcrecordid>eNrjZFAPDXZV8HdTcPQL8XTy9A_xdA5WcAxWCHN0dvb0c1VwdPEKDQPKBfMwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUkvigUCNjIyMjE0NnI2MilAAAkE8jWA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>USE OF ANTIBIOTICS AS VACCINE ADJUVANTS</title><source>esp@cenet</source><creator>LEJ REHNDI DIN ; O`KHARA MAJKL KENNET ; MAKGEHJVIN DEHVID ROSS</creator><creatorcontrib>LEJ REHNDI DIN ; O`KHARA MAJKL KENNET ; MAKGEHJVIN DEHVID ROSS</creatorcontrib><description>FIELD: medicine, chemical-pharmaceutical industry, microbiology, pharmacy. ^ SUBSTANCE: invention relates to an adjuvant composition comprising antibacterial agent azalid tulathromycin wherein azalid acts as adjuvant. Also, invention relates to vaccine comprising some components and involving: (A) at least one antigen wherein antigen is chosen from group consisting of M. haemolytica antigen, M. haemolytica leukotoxin, M. haemolytica capsule antigen, M. haemolytica soluble antigen, or their mixture, and (b) at least one azalid, for example, tulathromycin wherein azalid acts as adjuvant. Adjuvant or vaccine compositions are used for prophylaxis and treatment of diseases caused by pathogenic factor, cancer cell or allergen in animal but not in human. Proposed adjuvant provides enhancing effectiveness of the vaccine composition. ^ EFFECT: improved and valuable medicinal properties of composition. ^ 10 cl, 16 tbl, 2 dwg, 5 ex</description><language>eng ; rus</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2008</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20080420&amp;DB=EPODOC&amp;CC=RU&amp;NR=2322241C2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20080420&amp;DB=EPODOC&amp;CC=RU&amp;NR=2322241C2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LEJ REHNDI DIN</creatorcontrib><creatorcontrib>O`KHARA MAJKL KENNET</creatorcontrib><creatorcontrib>MAKGEHJVIN DEHVID ROSS</creatorcontrib><title>USE OF ANTIBIOTICS AS VACCINE ADJUVANTS</title><description>FIELD: medicine, chemical-pharmaceutical industry, microbiology, pharmacy. ^ SUBSTANCE: invention relates to an adjuvant composition comprising antibacterial agent azalid tulathromycin wherein azalid acts as adjuvant. Also, invention relates to vaccine comprising some components and involving: (A) at least one antigen wherein antigen is chosen from group consisting of M. haemolytica antigen, M. haemolytica leukotoxin, M. haemolytica capsule antigen, M. haemolytica soluble antigen, or their mixture, and (b) at least one azalid, for example, tulathromycin wherein azalid acts as adjuvant. Adjuvant or vaccine compositions are used for prophylaxis and treatment of diseases caused by pathogenic factor, cancer cell or allergen in animal but not in human. Proposed adjuvant provides enhancing effectiveness of the vaccine composition. ^ EFFECT: improved and valuable medicinal properties of composition. ^ 10 cl, 16 tbl, 2 dwg, 5 ex</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2008</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFAPDXZV8HdTcPQL8XTy9A_xdA5WcAxWCHN0dvb0c1VwdPEKDQPKBfMwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUkvigUCNjIyMjE0NnI2MilAAAkE8jWA</recordid><startdate>20080420</startdate><enddate>20080420</enddate><creator>LEJ REHNDI DIN</creator><creator>O`KHARA MAJKL KENNET</creator><creator>MAKGEHJVIN DEHVID ROSS</creator><scope>EVB</scope></search><sort><creationdate>20080420</creationdate><title>USE OF ANTIBIOTICS AS VACCINE ADJUVANTS</title><author>LEJ REHNDI DIN ; O`KHARA MAJKL KENNET ; MAKGEHJVIN DEHVID ROSS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_RU2322241C23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; rus</language><creationdate>2008</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>LEJ REHNDI DIN</creatorcontrib><creatorcontrib>O`KHARA MAJKL KENNET</creatorcontrib><creatorcontrib>MAKGEHJVIN DEHVID ROSS</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LEJ REHNDI DIN</au><au>O`KHARA MAJKL KENNET</au><au>MAKGEHJVIN DEHVID ROSS</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>USE OF ANTIBIOTICS AS VACCINE ADJUVANTS</title><date>2008-04-20</date><risdate>2008</risdate><abstract>FIELD: medicine, chemical-pharmaceutical industry, microbiology, pharmacy. ^ SUBSTANCE: invention relates to an adjuvant composition comprising antibacterial agent azalid tulathromycin wherein azalid acts as adjuvant. Also, invention relates to vaccine comprising some components and involving: (A) at least one antigen wherein antigen is chosen from group consisting of M. haemolytica antigen, M. haemolytica leukotoxin, M. haemolytica capsule antigen, M. haemolytica soluble antigen, or their mixture, and (b) at least one azalid, for example, tulathromycin wherein azalid acts as adjuvant. Adjuvant or vaccine compositions are used for prophylaxis and treatment of diseases caused by pathogenic factor, cancer cell or allergen in animal but not in human. Proposed adjuvant provides enhancing effectiveness of the vaccine composition. ^ EFFECT: improved and valuable medicinal properties of composition. ^ 10 cl, 16 tbl, 2 dwg, 5 ex</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; rus
recordid cdi_epo_espacenet_RU2322241C2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title USE OF ANTIBIOTICS AS VACCINE ADJUVANTS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A43%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LEJ%20REHNDI%20DIN&rft.date=2008-04-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ERU2322241C2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true